ATOX1 and breast carcinoma: Additionally, the pharmacological inhibition of ATOX1, using the inhibitor DCAC50 [108], which also blocks copper transfer to other cuproenzymes, reduced cell proliferation in a panel of cell lines including human lung cancer, leukemia cancer and breast cancer cell lines with minimal effects in the parental cells [108].